Ortho-McNeil has certain performance obligations related to promotional activities for these products. Subject to FDA approval, Ralivia(TM) FlashDose(R) will be available in 50mg, tablets by prescription only. Patent and Trademark Office that are expected to be issued, and listed in the U. Our actual results could differ materially from those discussed ultram er in, or implied by, these forward-looking statements. Both Biovail and Ortho-McNeil retain an option to extend the co-promotion arrangement by mutual consent for additional two-year periods. Both formulations have already been approved by the United States Food and Drug ultram er administration (FDA). Total sales for tramadol immediate release products were $150 million for the Ultram er same period. Swallowing difficulty or dysphagia itself is a frequent complication ultram er of a number of diseases including stroke, Parkinson’s disease and commonly associated with the progression of aging and is a major problem in the care of the elderly. Includes Extended-Release and Orally Disintegrating Tablet Formulations; — Launch Under Ultram(R) Brand Names Planned for Early 2006; — Biovail Receives $60-Million Supply Prepayment; — Biovail’s Supply Price Reaches 37. 5% of Partner’s Net Selling Price Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that a subsidiary has entered into a supply agreement with Ortho-McNeil, Inc. , a Johnson & Johnson company, for the marketing and distribution of a once-daily, extended-release (ER) formulation and an orally disintegrating (ODT), immediate-release formulation of tramadol hydrochloride ultram er in the United States and Puerto Rico. Ultram(R) ODT, which Ultram er is indicated for moderate to moderately severe pain, received FDA approval in May 2005, and will be available in a 50mg dosage strength. The supply prices go up to 37. 5% of Ortho-McNeil’s net selling price, depending on the year of sale, peaking in 2007 and beyond. Forward-Looking Statements Statements ultram er made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. Commercial Operations Business Model "The alliance with Ortho-McNeil validates Biovail’s new commercialization strategy in the U. , " said Dr. Safe Harbor statement under the Private Securities ultram er litigation Reform Act of 1995. Biovail recently announced the filing of Ralivia(TM) ER a once daily, extended release form of tramadol. Forward-looking statements include, but are not necessarily limited to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. Integrated Communications, a unit of Lowe Healthcare Worldwide, won a prelaunch med-ed assignment for Ultram ER, a chronic pain drug from J&J’s PriCara unit, the ultram er agency’s third PriCara hospital antibiotic win. Ultram(R) ER, which is indicated for moderate to moderately severe chronic pain, received FDA approval in September 2005 and will be available in 100mg, 200mg and 300mg dosage strengths. In May 2007, the Company received an approvable letter from the FDA pertaining to its NDA for CIP-TRAMADOL ER. "The ability to leverage the Ultram(R) name is a competitive advantage that should provide Ortho-McNeil’s world-class sales force, and Biovail’s specialty sales force, an opportunity to quickly establish a significant ultram er market position for Ultram(R) ER. " ultram er ultram(r) ER, which is indicated for moderate to moderately severe chronic pain, received FDA approval on September 8, 2005, and will be available in 100mg, 200mg and 300mg dosage strengths. Physicians Academy for Clinical and Management Excellence has hired Sherlyn Celone and Heidi Katz, RPh, as SVPs of strategic education.